ALDX - CIK 0001341235
Aldeyra Therapeutics, Inc. (ALDX) reported net income of -$33.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$33.85M | +39.4% |
| FY 2024 | -$55.85M | -48.8% |
| FY 2023 | -$37.54M | +39.5% |
| FY 2022 | -$62.02M | -7.4% |
| FY 2021 | -$57.78M | -53.8% |
| FY 2020 | -$37.55M | +38.3% |
| FY 2019 | -$60.83M | -56.4% |
| FY 2018 | -$38.89M | -74.1% |
| FY 2017 |
Aldeyra Therapeutics, Inc. (ALDX) reported net income of -$33.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Aldeyra Therapeutics, Inc.'s net income declined from -$2.38M to -$33.85M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$22.34M |
| -19.5% |
| FY 2016 | -$18.70M | -54.7% |
| FY 2015 | -$12.09M | -133.1% |
| FY 2014 | -$5.19M | -139.7% |
| FY 2013 | $13.06M | +156.6% |
| FY 2012 | -$23.07M | -870.3% |
| FY 2011 | -$2.38M | - |